Animal Testing Program. Promptly following the Effective Date, DiaTex shall commence a program of animal drug testing for demonstrating the improved efficacy of at least one of the Enantiomers, with the objective of providing sufficient data and justification to file at least one Enantiomer Patent (the “Animal Testing Program”). DiaTex shall bear all costs relating to the Animal Testing Program.
Appears in 3 contracts
Sources: License and Development Agreement (CymaBay Therapeutics, Inc.), License and Development Agreement (CymaBay Therapeutics, Inc.), License and Development Agreement (CymaBay Therapeutics, Inc.)